definiens: ) directed to the Target ( as defined in the Agreeme nt ) ( i.e., G12C ), and further are parties to that certa in Drug Discovery Collaboration Option Agreement da ted June 7, 2017, as amended ( herein, the ), di rected to K - Ras G12D ( herein referred to as the ) ; Whereas, Mirati exercised the Option pursuant to the Agreem ent effective as of April 1, 2016 ; and Whereas, Mirati and [COMPANY] desire to amend the Agreement to provide to each Party non - exclusive licenses under the Collaboration Technology with re spect to the development, manufacture and commercia lization of compounds and products [ * * * ] Non - Exclusive Targe ts ( as defined herein ) ; and Whereas, Mirati and [COMPANY] desire to amend the Agreement wit h respect to the rights of each Party in the event of termination of the Agreement ; Now, Therefore, in consideration of the foregoing premises and the mutual covenants set forth below, and for other good and valuable consideration, rece ipt of which is hereby acknowledged, Mirati and Arr ay hereby agree as follows : 1 . Definitions ( Generally ) . Any capitalized terms used and defined herein shall hav e the meaning ascribed to such terms herein, and any capitalized terms used b ut not defined herein shall have the meaning ascrib ed to such terms in the Agreement